Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas - Thompson, John A.; Motzer, Robert J.; Molina, Ana M.; Choueiri, Toni K.; Heath, Elisabeth I.; Redman, Bruce G.; Sangha, Randeep S.; Ernst, D. Scott; Pili, Roberto; Kim, Stella K.; Reyno, Leonard; Wiseman, Aya; et al. (Clinical Cancer Research, 2018)
Keywords: Aged; Aged, 80 and over; Animals; Antibodies, Anti-Idiotypic; Antibodies, Anti-Idiotypic - administration & dosage; Antibodies, Anti-Idiotypic - adverse effects; Carcinoma, Renal Cell; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - pathology; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Female; Humans; Immunoconjugates; Immunoconjugates - administration & dosage; Immunoconjugates - adverse effects; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oligopeptides; Oligopeptides - administration & dosage; Oligopeptides - adverse effects; Phosphoric Diester Hydrolases; Phosphoric Diester Hydrolases - genetics; Phosphoric Diester Hydrolases - immunology; Pyrophosphatases; Pyrophosphatases - genetics; Pyrophosphatases - immunology